Biosense Webster, Inc. (JNJ) Release: First Patient Enrolled in reMARQable Clinical Study Evaluating the Safety and Efficacy of Multi-Electrode nMARQ Pulmonary Vein Isolation System in the Treatment of Paroxysmal Atrial Fibrillation
5/9/2013 11:12:49 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DIAMOND BAR, Calif.--(BUSINESS WIRE)--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, today announced the first patient has been enrolled in the reMARQable clinical study. ReMARQable will assess the safety and efficacy of the use of the nMARQ™ Pulmonary Vein Isolation System to treat paroxysmal atrial fibrillation. Atrial fibrillation (Afib) is a heart rhythm disorder which affects approximately 20 million people worldwide.
Help employers find you! Check out all the jobs and post your resume.
comments powered by